Home Technology Legend Biotech (LEGN) Tests Its Valuation After Fresh CARVYKTI Five Year Data
Technology

Legend Biotech (LEGN) Tests Its Valuation After Fresh CARVYKTI Five Year Data

Share


Legend Biotech (LEGN) moved back into focus after releasing five-year follow-up data from its CARTITUDE-2 Cohort A study of CARVYKTI in relapsed or refractory multiple myeloma patients.

Despite the encouraging CARTITUDE-2 update, Legend Biotech’s recent trading tells a more cautious story. The share price is down about 3.9% over the past day and roughly 13.7% over 30 days, contributing to a 1-year total shareholder return decline of 42.1% and a 5-year total shareholder return decline of 65.3%. This signals fading momentum as investors reassess both opportunity and risk around CARVYKTI’s long-term profile.

Scan beyond Legend Biotech and line up other potential rebound stories in high-risk, high-reward territory with the hand-picked 8 elite penny stocks with strong financials.

Legend Biotech appears to have a compelling therapy story, yet the share price has slipped significantly over the past year. Is this a strong business being mispriced, or is the recent drop a fair reset of expectations?

Most Popular Narrative: 60% Undervalued

Legend Biotech last closed at $18.57, while the most followed narrative assigns a fair value of about $46.81. As a result, the gap between price and expectations is wide and puts the focus squarely on the long-term CAR-T story.

Robust innovation pipeline, including next-generation CAR-Ts and in vivo/off-the-shelf cell therapy technologies (e.g., TaVec platform), positions Legend to capitalize on rising demand for advanced, personalized therapies amid secular increases in cancer incidence and sustained healthcare investment, supporting future revenue streams and risk diversification.

See why 26 investors see Legend Biotech as 60% undervalued.

That framework uses a 7.62% discount rate and ties the $46.81 fair value to analyst expectations for revenue growth, profitability and margins over the coming years, rather than to last quarter’s headlines. The result is a narrative that views recent share price weakness alongside forecasts that Legend Biotech could move from a loss of $91.5 million today to meaningful earnings if those assumptions play out.

Result: Fair Value of $46.81 (UNDERVALUED)

Still, the bullish Legend Biotech narrative could unravel quickly if CARVYKTI loses share to rival therapies or if heavy R&D spend delays any path to profitability.

Find out about the key risks to this Legend Biotech narrative.

Next Steps

Mixed messages on Legend Biotech so far, right? If the story feels incomplete, move quickly, review the data yourself, then weigh the 4 key rewards

Looking for more Legend Biotech investment ideas?

Do not stop with Legend Biotech. Use the Simply Wall Street Screener to quickly surface fresh stock ideas that match the kind of risk and return profile you want.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include LEGN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com



Source link

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles
Technology

UK operation wards off risk of cyber-attack on supermarket fridges and freezers | Cybercrime

A secret government cybersecurity operation recently warded off the risk of a...

Technology

Fridge hacks: UK firms race to secure refrigeration systems

Tens of thousands of fridges and freezers at UK supermarkets, warehouses, restaurants,...

Technology

Secret operation protects thousands of freezers from being hacked across the UK | News UK

Earlier this month, thousands of refrigerators in Europe were targeted (Picture: Getty)...

Technology

UK spy chiefs in behind the scenes security operation to protect shops from fridge cyber attacks

Reports say experts have been working round-the-clock to plug potential gaps in...